Blog - Page 2522 of 5709

ThursdayDec 22, 2016 9:53 am

QualityStocks Keeps Investors Abreast of Small-cap Market’s Latest and Greatest

There’s a barrage of financial information available at any given moment – while it initially sounds great, investors need a quick, clear-cut method to dig through the madness to find their next great investment opportunity. QualityStocks keeps investors up-to-date on everything related to the small-cap and micro-cap markets by offering several ways to filter through the information to easily find the material needed. The QualityStocks Blog is updated daily; investors can read about leading players in the small-cap and micro-cap markets and discover emerging companies flying under the radar along the way. We’re not just committed to highlighting rising stocks;…

WednesdayDec 21, 2016 10:12 am

OurPet’s Company (OPCO), Growing 50% Faster than the Industry Rate, Is a Bargain Buy

In the world of value investing, not all that is gold glitters… like Ohio-based OurPet’s Company, for example. OurPet’s Company (OTCQX: OPCO) is a leading proprietary pet supply company that designs, produces, and markets a broad line of innovative, high-quality accessory and consumable pet products under the OurPets® and Pet Zone® brands in the U.S. and international markets. Its yearly revenues have been rising at a steady clip since its inception over 20 years ago and so, too, have its profits. Yet OPCO’s valuation is way below what you might expect. Could this be a case of investors eschewing value…

TuesdayDec 20, 2016 10:18 am

CytoDyn Inc. (CYDY) Targets HIV as its Lead Product, PRO 140, Enters Phase 3 Clinical Development

CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the Washington-based biotech is showing a lot of progress nearing major milestones. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) to healthy cells. PRO 140 is presently at the Phase 3 clinical trial stage. For the millions worldwide with HIV/AIDS, PRO 140 could offer the promise of a more robust bodyguard from further viral insult with potentially fewer side effects and hardly any toxicity. HIV,…

MondayDec 19, 2016 1:02 pm

CytoDyn Inc. (CYDY) is “One to Watch”

CytoDyn Inc. (OTCQB: CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection. PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral…

MondayDec 19, 2016 10:16 am

Rennova Health, Inc. (NASDAQ: RNVA) Creating the Next Generation of Health Care

Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does. The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting…

FridayDec 16, 2016 4:26 pm

Singlepoint, Inc. (SING) CEO Comments on Company’s Above-Average Volume in Interview on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular,…

FridayDec 16, 2016 2:48 pm

National Waste Management Holdings, Inc. (NWMH) Set to Capitalize on Untapped East Coast Opportunities

The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://dtn.fm/tKM4H) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily…

FridayDec 16, 2016 12:23 pm

PharmaCyte Biotech, Inc. (PMCB) Pre-IND Meeting with FDA Makes ATM Funding Possible

For California-based PharmaCyte Biotech, Inc. (OTCQB: PMCB), a light at the end of the pipeline tunnel has become visible as one piece of good news follows another. The approval by the FDA to entertain a Pre-Investigational New Drug (Pre-IND) submission from the company sent PMCB stock soaring to triple its pre-approval value. The resulting market cap made PharmaCyte ‘primarily eligible’ to register securities for sale in an at-the-market (ATM) offering, which it now plans to do through Chardan Capital. To make an ATM offering requires that the issuer be eligible, on a primary basis, to use a shelf registration statement…

FridayDec 16, 2016 10:10 am

Higher Price Target for Ocera Therapeutics (NASDAQ: OCRX) as Hepatic Encephalopathy Treatment Study Moves Forward

An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://dtn.fm/J0h97) released on December 8. The report reiterates a 'Buy' rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis. The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead…

ThursdayDec 15, 2016 3:59 pm

GainClients, Inc. (GCLT) Offering Buyers Simplified Home Search Tools with Comprehensive Results

U.S. home prices are going up steadily, having reached the highest peak in September after 2006’s real estate boom, a growth primarily driven by rising demand and a scarce inventory. The price hike came as a surprise to most real estate professionals, who expected a significant market slowdown in the last few months of 2016. While 2017 is likely to see more moderate growth, the market will continue to expand nonetheless, Realtor.com (http://dtn.fm/HdG6u) experts believe, as two of America’s largest generations - Millennials and baby boomers, are reaching a stage in their lives that typically motivates people to buy a…

Site Search

Company Search